Bausch Health Companies (TSE:BHC) Shares Up 24.6% - Time to Buy?

Key Points

• Bausch Health shares surged 24.6% to C$12.05 on unusually heavy trading after the company reported quarterly earnings of C$2.52 per share and revenue of approximately C$4.19 billion, exceeding expectations.
• Management indicated 2026 revenue of roughly $5.525 billion to $5.625 billion and authorized a C$70 million share buyback covering up to 1.9% of outstanding shares, potentially supporting the stock.
• Despite the strong results, investors face near-term Xifaxan headwinds, while analysts maintain a consensus “Hold” rating; the company also carries significant financial risk, including a quick ratio of 0.58 and negative net margin.

Bausch Health Companies Inc. (TSE:BHC - Get Free Report)'s share price shot up 24.6% during trading on Thursday. The stock traded as high as C$12.09 and last traded at C$12.05. Approximately 1,815,131 shares were traded during trading, an increase of 234% from the average daily volume of 544,187 shares. The stock had previously closed at C$9.67.

Key Bausch Health Companies News

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Stronger-than-expected quarterly performance: Bausch Health reported C$2.52 in earnings per share and approximately C$4.19 billion in quarterly revenue. Reports characterized third-quarter profit as higher than the prior-year period and described the results as an earnings beat. Bausch Health Companies Inc. Q3 Profit Climbs
• Positive Sentiment: Raised or reaffirmed growth expectations: Management indicated 2026 revenue of roughly $5.525 billion to $5.625 billion, giving investors greater visibility into the company’s full-year performance. Bausch Health signals 2026 revenue guidance
• Positive Sentiment: Share buyback supports the stock: The board authorized a repurchase of up to C$70 million of shares, or approximately 1.9% of the outstanding stock. The authorization may signal that management views the shares as undervalued and could provide incremental support for per-share results. Bausch Health share buyback report
• Neutral Sentiment: Management commentary remains important: The earnings call focused on operating performance, the full-year outlook and product-specific trends, giving investors additional detail on the company’s execution and financial priorities. Bausch Health Q3 2026 earnings call transcript
• Negative Sentiment: Xifaxan could weigh on the fourth quarter: Bausch Health warned of Q4 headwinds for Xifaxan, creating a near-term risk to sales and potentially limiting the upside from the strong third-quarter results. Xifaxan headwinds and 2026 outlook

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded Bausch Health Companies to a "hold" rating in a report on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating. According to MarketBeat, Bausch Health Companies has a consensus rating of "Hold".

Bausch Health Companies Trading Up 25.4%

The company has a debt-to-equity ratio of -1,173.29, a quick ratio of 0.58 and a current ratio of 1.44. The firm has a market cap of C$4.54 billion, a price-to-earnings ratio of -4.13, a P/E/G ratio of 0.21 and a beta of 0.82. The company's 50-day moving average is C$8.65 and its 200-day moving average is C$7.93.

Bausch Health Companies (TSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported C$2.52 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%. The company had revenue of C$4.19 billion during the quarter. On average, research analysts predict that Bausch Health Companies Inc. will post 5.55 earnings per share for the current year.

Bausch Health Companies declared that its board has initiated a share buyback program on Wednesday, October 28th that authorizes the company to buy back C$70 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 1.9% of its stock through open market purchases. Share buyback programs are usually a sign that the company's board believes its shares are undervalued.

About Bausch Health Companies

Bausch Health Companies Inc NYSE: BHCTSX: BHC is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.